Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Cash & Current Investments (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Cash & Current Investments for 10 consecutive years, with $29.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 52.84% year-over-year to $29.0 million, compared with a TTM value of $29.0 million through Dec 2025, down 52.84%, and an annual FY2025 reading of $29.0 million, down 52.84% over the prior year.
  • Cash & Current Investments was $29.0 million for Q4 2025 at VYNE Therapeutics, up from $17.6 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $119.5 million in Q1 2021 and bottomed at $15.4 million in Q3 2023.
  • Average Cash & Current Investments over 5 years is $51.8 million, with a median of $42.8 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments skyrocketed 278.51% in 2024, then tumbled 77.47% in 2025.
  • Year by year, Cash & Current Investments stood at $42.2 million in 2021, then dropped by 26.84% to $30.9 million in 2022, then soared by 201.71% to $93.3 million in 2023, then plummeted by 34.03% to $61.5 million in 2024, then tumbled by 52.84% to $29.0 million in 2025.
  • Business Quant data shows Cash & Current Investments for VYNE at $29.0 million in Q4 2025, $17.6 million in Q2 2025, and $22.1 million in Q1 2025.